F
Friedrich Grimminger
Researcher at University of Giessen
Publications - 431
Citations - 33019
Friedrich Grimminger is an academic researcher from University of Giessen. The author has contributed to research in topics: Pulmonary hypertension & Hypoxia (medical). The author has an hindex of 83, co-authored 402 publications receiving 30002 citations. Previous affiliations of Friedrich Grimminger include Goethe University Frankfurt.
Papers
More filters
Journal ArticleDOI
Sildenafil citrate therapy for pulmonary arterial hypertension.
Nazzareno Galiè,Hossein Ardeschir Ghofrani,Adam Torbicki,Robyn J. Barst,Lewis J. Rubin,David B. Badesch,Thomas R. Fleming,Tamiza Parpia,Gary Burgess,Angelo Branzi,Friedrich Grimminger,Marcin Kurzyna,Gérald Simonneau +12 more
TL;DR: Among the 222 patients completing one year of treatment with sildenafil monotherapy, the improvement from baseline at one year in the distance walked in six minutes was 51 m, and the incidence of clinical worsening did not differ significantly between the patients treated with s Bildenafils and those treated with placebo.
Journal ArticleDOI
Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension
Hossein Ardeschir Ghofrani,Andrea Maria D'Armini,Friedrich Grimminger,Marius M. Hoeper,Pavel Jansa,Nick H. Kim,Eckhard Mayer,Gérald Simonneau,Martin R. Wilkins,Arno Fritsch,Dieter Neuser,Gerrit Weimann,Chen Wang +12 more
TL;DR: Riociguat significantly improved exercise capacity and pulmonary vascular resistance in patients with chronic thromboembolic pulmonary hypertension.
Journal ArticleDOI
Reversal of experimental pulmonary hypertension by PDGF inhibition.
Ralph T. Schermuly,Eva Dony,Hossein Ardeschir Ghofrani,Soni Savai Pullamsetti,Rajkumar Savai,Markus Roth,Akylbek Sydykov,Ying Ju Lai,Norbert Weissmann,Werner Seeger,Friedrich Grimminger +10 more
TL;DR: STI571 reverses vascular remodeling and cor pulmonale in severe experimental pulmonary hypertension regardless of the initiating stimulus, and offers a unique novel approach for antire-modeling therapy in progressed pulmonary hypertension.
Journal ArticleDOI
Riociguat for the Treatment of Pulmonary Arterial Hypertension
Hossein Ardeschir Ghofrani,Nazzareno Galiè,Friedrich Grimminger,Ekkehard Grünig,Marc Humbert,Zhi-Cheng Jing,Anne Keogh,David Langleben,Michael Ochan Kilama,Arno Fritsch,Dieter Neuser,Lewis J. Rubin +11 more
TL;DR: Riociguat significantly improved exercise capacity and secondary efficacy end points in patients with pulmonary arterial hypertension and showed significant improvements in pulmonary vascular resistance, NT-proBNP levels, World Health Organization functional class, and time to clinical worsening.
Journal ArticleDOI
Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial
Hossein Ardeschir Ghofrani,Ralph Wiedemann,Frank Rose,Ralph T. Schermuly,Horst Olschewski,Norbert Weissmann,Andreas Günther,Dieter Walmrath,Werner Seeger,Friedrich Grimminger +9 more
TL;DR: Sildenafil causes preferential pulmonary vasodilation and improves gas exchange in patients with severe lung fibrosis and secondary pulmonary hypertension, and ratio of pulmonary to systemic vascular resistance decreased only in individuals who received nitric oxide and sildanafil.